Understanding moderate to severe tricuspid regurgitation and its outcomes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on the characteristics and prognosis of patients with moderate or severe tricuspid regurgitation (TR). The tricuspid valve, often overlooked in echocardiography, plays a crucial role in heart function, and TR can lead to significant complications, including right heart failure. The study aims to better define the timing for surgical intervention in patients with TR, as current guidelines are vague due to a lack of prognostic data. By utilizing transthoracic echocardiography, the study will assess the hemodynamic impact of TR and its progression over time.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age \>18 ans
* inclusion criteria: moderate or severe tricuspid regurgitation
* exclusion criteria: Refusal to participate/ prior surgery of the tricuspid valve

Where it's running

• CHU Amiens-Picardie
  Amiens, France Recruiting

Study contacts

• Principal investigator: Christophe TRIBOUILLOY, Pr — Chu Amiens-Picardie
• Study coordinator: Christophe TRIBOUILLOY, Pr
• Email: Tribouilloy.Christophe@chu-amiens.fr
• Phone: 03 22 45 58 85

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• TruGamma tricuspid valve replacement for high-risk patients

  This trial tests the TruGamma tricuspid valve replacement system in high-risk patients with severe tricuspid regurgitation to see if it is safe and helps symptoms when added to standard medical care.

  Recruiting Jiangsu Trulive Medical Co., Ltd · Beijing, Beijing Municipality · NCT07691307

• Transcatheter Tricuspid Valve Replacement for Severe Tricuspid Regurgitation

  This trial tests the Laplace TTVR System to see if it safely and effectively treats adults with severe tricuspid regurgitation.

  Recruiting at 2 sites Laplace Interventional, Inc · Tulsa, Oklahoma and 1 other locations · NCT07687485

• TRIFORMIS RESILIA heart valve real-world results in tricuspid disease

  A real-world, observational study to see how the Edwards TRIFORMIS RESILIA tricuspid heart valve performs in adults needing tricuspid valve replacement.

  Recruiting Edwards Lifesciences · Carmel, Indiana · NCT07684313

• Vyne TriNova Transcatheter Tricuspid Valve Replacement study for severe tricuspid regurgitation

  This trial tests the VDyne TriNova system in adults with symptomatic severe tricuspid regurgitation to see if it is safe and helps heart symptoms compared with an alternative device.

  Recruiting at 12 sites VDyne, Inc. · Phoenix, Arizona and 11 other locations · NCT07516444

• Tracking progression and consequences of heart valve disease

  This project will follow adults with moderate or worse valve disease to see if clinical tests and imaging can predict when their condition will get worse.

  Recruiting at 15 sites Second Affiliated Hospital, Zhejiang University, School of Medicine · Fuzhou, Fujian and 14 other locations · NCT07267117

• Investigating multiple and mixed heart valve diseases

  This study looks at how common different types of heart valve diseases are and their features by gathering information from patients around the world who have been diagnosed with these conditions.

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris, Île-de-France Region · NCT06235385

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.